A First in HumanTrial to Evaluate The Safety, Tolerability, And Pharmacokinetics Of PF-06755347

PHASE1

Phase

TERMINATED

Status

Enrollment

INDUSTRY

Sponsor class

Stopped The Sponsor has decided to terminate the above referenced clinical study for business reasons. There were no safety concerns that led to this decision and there was no impact to participant safety.

Conditions

Healthy
Primary Immune Thrombocytopenia
Polyradiculoneuropathy, Chronic Inflammatory Demyelinating

Interventions

DRUG: PF-06755347 intravenous healthy participant
DRUG: Placebo intravenous healthy participant
DRUG: PF-06755347 subcutaneous healthy participant
DRUG: Placebo subcutaneous healthy participant
DRUG: PF-06755347 subcutaneous ITP

Sponsor

Pfizer